Descartes-11 Trial Tests RNA-Engineer Cell Therapy in Multiple Myeloma
Cartesian Therapeutics launches a trial of Descartes-11, which is designed to express CAR-T molecules transiently.
Multiple Myeloma
Multiple Myeloma Treatment Regimens
Find detailed drug treatment regimens for multiple myeloma, including primary therapy for both transplant candidates and non-transplant candidates.
Cost a Barrier to Daratumumab-Containing Regimens in First-Line Treatment of Multiple Myeloma
A cost analysis shows daratumumab may be better used as a second-line treatment for transplant-ineligible patients with multiple myeloma.
Durable Erythroid Response With Lenalidomide, Epoetin Alfa in Refractory Myelodysplastic Syndromes
A phase 3 trial suggests higher responses when epoetin alfa is added to lenalidomide in treatment of erythropoietin-refractory myelodysplastic syndromes.
Carriers of CALR Mutations at Decreased Risk for Thrombotic Events Among Patients With Essential Thrombocythemia
Researchers determined the impact of mutations in the CALR gene on thrombotic risk for patients with essential thrombocythemia.
PARP Inhibition Associated With Increased Risk for Secondary MDS, AML
Investigators estimated the risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) related to PARP inhibition.
Study Finds Low Adherence to Lenalidomide Therapy in Multiple Myeloma
Lenalidomide is typically prescribed to individuals with multiple myeloma who have received at least 1 prior therapy.
Effects of Daratumumab on Patient-Reported Outcomes, HRQOL in Newly Diagnosed Multiple Myeloma
Investigators reported the results of the phase 3 MAIA trial on HRQOL outcomes in patients with transplant-ineligible, newly diagnosed MM.
Laboratory Markers Found to Correlate With Symptom Burden in Relapsed/Refractory Multiple Myeloma
Study finds correlation between certain laboratory markers and symptom burden in patients with relapsed/refractory multiple myeloma.
Beta Blocker Usage Associated With Prolonged PFS in R/R Multiple Myeloma
This retrospective analysis explored the impact of beta blocker therapy on survival in patients with relapsed or refractory multiple myeloma receiving pomalidomide.
-
Loading...
-
Loading...
Next post in Multiple Myeloma
